Cellectis (CLLS) Non-Current Assets (2013 - 2026)
Cellectis' (CLLS) quarterly Non-Current Assets came in at $84.6 million in Q1 2026, down 8.26% year-on-year from $92.3 million in Q1 2025, and down 4.34% quarter-over-quarter from $88.5 million in Q4 2025.
Cellectis (CLLS) Non-Current Assets (2013 - 2026) Analysis & Trends
Cellectis' Non-Current Assets history runs 14 years deep, the most recent figure standing at $84.6 million for Q1 2026.
- On a quarterly basis, Non-Current Assets fell 8.26% year-over-year to $84.6 million in Q1 2026; TTM through Mar 2026 was $84.6 million, a 8.26% decrease from a year earlier, with the FY2025 full-year figure at $88.5 million, down 8.29% from the prior year.
- Non-Current Assets eased to $84.6 million in Q1 2026 per CLLS's latest filing, from $88.5 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $152.0 million in Q1 2022 and bottomed at $84.6 million in Q1 2026.
- The 5-year median for Non-Current Assets is $113.2 million (2023), against an average of $112.0 million.
- Across the five-year window, Non-Current Assets decreased 25.05% in 2022 and rose 21.69% in 2025, its largest moves.
- Year by year, Non-Current Assets stood at $117.4 million in 2022, then slipped by 13.75% to $101.3 million in 2023, then retreated by 4.73% to $96.5 million in 2024, then declined by 8.29% to $88.5 million in 2025, then declined by 4.34% to $84.6 million in 2026.
- Per Business Quant, the three latest CLLS Non-Current Assets figures stand at $84.6 million (Q1 2026), $88.5 million (Q4 2025), and $121.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - | 84.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.64 Mn |
| Dec 31, 2025 | 88.48 Mn |
| Sep 30, 2025 | 121.85 Mn |
| Jun 30, 2025 | 123.33 Mn |
| Mar 31, 2025 | 92.26 Mn |
| Dec 31, 2024 | 96.48 Mn |
| Sep 30, 2024 | 101.45 Mn |
| Jun 30, 2024 | 101.34 Mn |
| Mar 31, 2024 | 96.39 Mn |
| Dec 31, 2023 | 101.27 Mn |
| Sep 30, 2023 | 113.21 Mn |
| Jun 30, 2023 | 114.39 Mn |
| Mar 31, 2023 | 114.04 Mn |
| Dec 31, 2022 | 117.41 Mn |
| Sep 30, 2022 | 139.31 Mn |
| Jun 30, 2022 | 145.72 Mn |
| Mar 31, 2022 | 152.02 Mn |
| Dec 31, 2021 | 156.65 Mn |
| Sep 30, 2021 | 177.04 Mn |
| Jun 30, 2021 | 177.21 Mn |